Q4 2020 13F Holders as of 12/31/2020
-
Type / Class
-
Equity / Common Stock, par value $0.001 par value per share
-
Shares outstanding
-
73.8M
-
Number of holders
-
77
-
Total 13F shares, excl. options
-
9.04M
-
Shares change
-
-1.32M
-
Total reported value, excl. options
-
$290M
-
Value change
-
-$48.4M
-
Number of buys
-
36
-
Number of sells
-
-29
-
Price
-
$32.07
Significant Holders of RELMADA THERAPEUTICS, INC. - Common Stock, par value $0.001 par value per share (RLMD) as of Q4 2020
90 filings reported holding RLMD - RELMADA THERAPEUTICS, INC. - Common Stock, par value $0.001 par value per share as of Q4 2020.
RELMADA THERAPEUTICS, INC. - Common Stock, par value $0.001 par value per share (RLMD) has 77 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 9.04M shares
of 73.8M outstanding shares and own 12.25% of the company stock.
Largest 10 shareholders include Avoro Capital Advisors LLC (1.53M shares), RTW INVESTMENTS, LP (1.51M shares), BlackRock Inc. (1.49M shares), VR Adviser, LLC (668K shares), VANGUARD GROUP INC (663K shares), PARSONS CAPITAL MANAGEMENT INC/RI (452K shares), STATE STREET CORP (304K shares), Point72 Asset Management, L.P. (285K shares), FRANKLIN RESOURCES INC (225K shares), and GEODE CAPITAL MANAGEMENT, LLC (206K shares).
This table shows the top 77 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.